Suppr超能文献

药物性骨丢失:欧洲的一大安全隐患。

Drug-induced bone loss: a major safety concern in Europe.

机构信息

a Laboratoire de Pharmacologie Médicale et Clinique, Equipe de Pharmacoépidémiologie de l'UMR INSERM 1027, Faculté de Médecine de l'Université Paul-Sabatier et Centre Midi-Pyrénées de PharmacoVigilance , de Pharmacoépidémiologie et d'Information sur le Médicament de l'UMR INSERM 1027, Centre Hospitalier Universitaire , Toulouse , France.

b The National Centre of Drug Information and Adverse Drug Reaction Monitoring , Hanoi University of Pharmacy , Hanoi , Vietnam.

出版信息

Expert Opin Drug Saf. 2018 Oct;17(10):1005-1014. doi: 10.1080/14740338.2018.1524868. Epub 2018 Sep 23.

Abstract

INTRODUCTION

Drug-induced bone loss remains the major cause of vertebral and hip fractures and significantly associated to morbidity and mortality. This article will review the common drugs identified as the causes of bone loss and the risk factors and management in European countries.

AREAS COVERED

Beyond glucorticoid - the most cause of osteoporosis, many different drugs could cause harmful skeletal disorders. The antiepileptics, hormonal therapy, GnRH antagonists, aromatase inhibitors are well-known cause of bone loss. Osteoporosis and fractures risk also increased with calcineurin inhibitors, antiretroviral drugs, selective inhibitors of serotonin reuptake, loop diuretics, heparins, oral anticoagulants, high doses of thyroxine and proton pump inhibitors.

EXPERT OPINION

Drugs are an important secondary cause of osteoporosis. Healthcare professionals should reassess the requirement for drugs and use the lowest dosage and shortest duration. Lifestyle changes, adequate calcium, vitamin D supplement, appropriate monitoring of bone status and initiating osteoporosis treatment if indicated are recommended when drugs having potential deleterious effects on bone are used, particularly in high risk patients. The update and further studies would provide concluded evidences of controversial drugs induced bone loss and determine the best prevention and treatment strategies.

摘要

简介

药物性骨丢失仍然是导致椎体和髋部骨折的主要原因,与发病率和死亡率密切相关。本文将回顾在欧洲国家被确定为导致骨丢失的常见药物以及相关风险因素和管理方法。

涵盖领域

除了糖皮质激素——最常见的骨质疏松症病因外,许多不同的药物也可能导致骨骼不良。抗癫痫药、激素治疗、促性腺激素释放激素拮抗剂、芳香化酶抑制剂是众所周知的导致骨丢失的药物。钙调神经磷酸酶抑制剂、抗逆转录病毒药物、选择性 5-羟色胺再摄取抑制剂、噻嗪类利尿剂、肝素、口服抗凝剂、大剂量甲状腺素和质子泵抑制剂也会增加骨质疏松症和骨折风险。

专家意见

药物是骨质疏松症的一个重要次要病因。医疗保健专业人员应重新评估药物的需求,并使用最低剂量和最短疗程。建议在使用可能对骨骼有潜在不良影响的药物时(尤其是在高风险患者中),改变生活方式,适当补充钙和维生素 D,适当监测骨骼状况,并在有必要时开始骨质疏松症治疗。更新和进一步的研究将为有争议的药物诱导骨丢失提供结论性证据,并确定最佳的预防和治疗策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验